Literature DB >> 822237

Functional and morphologic changes during experimental Rocky Mountain spotted fever in guinea pigs.

J B Moe, D F Mosher, R H Kenyon, J D White, J L Stookey, L R Bagley, D P Fine.   

Abstract

Experimental Rocky Mountain spotted fever was studied in guinea pigs following intraperitoneal inoculation of 10(7) Rickettsia rickettsii. After a 2-day incubation period, animals developed fever, progressive emaciation, and scrotal swelling with necrosis. Vasculitis, with increased small vessel permeability for colloidal carbon, was evident in cremaster muscles as early as 1 day after inoculation. Inflammatory changes in vessels became progressively more severe as numbers of circulating rickettsiae increased. Thrombosis and vascular occlusion were first evident on day 4. Mild thrombocytopenia developed, coinciding with the development of vasculitis, and preceding the appearance of either fibrin-split products in blood or thrombi in vessels. Rickettsiae were first detected in blood on day 2; peak rickettsemia occurred on days 5 to 8. Rickettsiae were demonstrated in inflamed vessels on day 5 and later, but not at earlier stages. Serum lysozyme concentration was moderately elevated and hemolytic complement was moderately depressed throughout the illness. Agglutinating antibody was present in low titers on days 3 to 10. Antibody titers increased on days 12 to 16 after the rickettsiae were cleared from blood. These studies indicate that vasculitis seen early in the course of Rocky Mountain spotted fever is the result of rickettsial infection, but is not dependent on the presence of rickettsiae in endothelial cells or other blood vessel components.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 822237

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

1.  The Rickettsia conorii autotransporter protein Sca1 promotes adherence to nonphagocytic mammalian cells.

Authors:  Sean P Riley; Kenneth C Goh; Timothy M Hermanas; Marissa M Cardwell; Yvonne G Y Chan; Juan J Martinez
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

2.  Effect of immunosuppression on Rickettsia rickettsii infection in guinea pigs.

Authors:  D H Walker; F W Henderson
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

3.  Prophylactic treatment of Rocky Mountain spotted fever.

Authors:  R H Kenyon; R G Williams; C N Oster; C E Pedersen
Journal:  J Clin Microbiol       Date:  1978-07       Impact factor: 5.948

4.  Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation.

Authors:  L A Sporn; V J Marder
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

5.  Identification of Rickettsia rickettsii in formalin-fixed, paraffin-embedded tissues by immunofluorescence.

Authors:  W C Hall; L R Bagley
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

6.  Rickettsia australis infection: a murine model of a highly invasive vasculopathic rickettsiosis.

Authors:  H M Feng; J Wen; D H Walker
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

Review 7.  Infection of the endothelium by members of the order Rickettsiales.

Authors:  Gustavo Valbuena; David H Walker
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

8.  Interferon-gamma and tumor necrosis factor-alpha exert their antirickettsial effect via induction of synthesis of nitric oxide.

Authors:  H M Feng; D H Walker
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

9.  Rocky Mountain spotted fever vaccine in an animal model.

Authors:  J D Folds; D H Walker; B C Hegarty; D Banasiak; J V Lange
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

10.  Suppression of cellular immune responses in guinea pigs infected with spotted fever group rickettsiae.

Authors:  C N Oster; R H Kenyon; C E Pedersen
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.